Therefore, albumin-adjusted GA could be used as a biomarker to directly reflect the cross-sectional both BVAS and BVAS assigned to renal manifestation in AAV patients. The gene discussed is ALB; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.